These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32530080)

  • 1. Acute Graft-versus-Host Disease: Emerging Insights and Updates into Detection, Prevention, and Treatment.
    DiMaggio E
    Pharmacotherapy; 2020 Aug; 40(8):788-807. PubMed ID: 32530080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Chen YB; Shah NN; Renteria AS; Cutler C; Jansson J; Akbari M; Chen C; Quadri S; Parfionovas A; Devine SM
    Blood Adv; 2019 Dec; 3(23):4136-4146. PubMed ID: 31821456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-
    Drobyski WR; Szabo A; Zhu F; Keever-Taylor C; Hebert KM; Dunn R; Yim S; Johnson B; D'Souza A; Eapen M; Fenske TS; Hari P; Hamadani M; Horowitz MM; Rizzo JD; Saber W; Shah N; Shaw B; Pasquini M
    Haematologica; 2018 Apr; 103(4):717-727. PubMed ID: 29351985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience.
    Yucebay F; Matthews C; Puto M; Li J; William B; Jaglowski SM; Penza SL; Vasu S; Benson DM; Andritsos LA; Devine SM; Efebera YA; Roddy JVF
    Leuk Lymphoma; 2019 Sep; 60(9):2223-2229. PubMed ID: 30764681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
    Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
    Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graft-vs-host disease following allogeneic hematopoietic cell transplantation.
    Pidala J
    Cancer Control; 2011 Oct; 18(4):268-76. PubMed ID: 21976245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging drugs for acute graft-versus-host disease.
    Khaled Y; Reddy P; Krijanovski O
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):219-32. PubMed ID: 19519285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease.
    Fløisand Y; Lundin KEA; Lazarevic V; Kristiansen JD; Osnes LTN; Tjønnfjord GE; Reims HM; Gedde-Dahl T
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):172-175. PubMed ID: 27777142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab as salvage treatment of refractory pulmonary acute graft-versus-host disease.
    Melgarejo-Ortuño A; Escudero-Vilaplana V; Revuelta-Herrero JL; Bailen R; Collado-Borrell R; Gomez-Centurión I; Oarbeascoa G; Kwon M; Herranz-Alonso A; Diez-Martin JL; Sanjurjo-Saez M
    J Oncol Pharm Pract; 2021 Apr; 27(3):751-755. PubMed ID: 32787560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of monoclonal antibodies in prophylaxis and treatment of acute and chronic graft-versus-host disease in 2011].
    Xhaard A; Hermet E; Bay JO; Peffault de Latour R
    Bull Cancer; 2011 Aug; 98(8):889-99. PubMed ID: 21835730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vedolizumab for treatment of steroid-refractory intestinal acute graft-versus-host disease: two cases report and literature review].
    Gao SC; Feng YM; Gao L; Kong PY; Zhu LD; Liu J; Wang L; Liu HF; Zhang X
    Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1046-1049. PubMed ID: 36709113
    [No Abstract]   [Full Text] [Related]  

  • 12. Tocilizumab for steroid refractory acute graft-versus-host disease.
    Roddy JV; Haverkos BM; McBride A; Leininger KM; Jaglowski S; Penza S; Klisovic R; Blum W; Vasu S; Hofmeister CC; Benson DM; Andritsos LA; Devine SM; Efebera YA
    Leuk Lymphoma; 2016; 57(1):81-5. PubMed ID: 26140610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.
    Abedin S; McKenna E; Chhabra S; Pasquini M; Shah NN; Jerkins J; Baim A; Runaas L; Longo W; Drobyski W; Hari PN; Hamadani M
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1689-1694. PubMed ID: 30965140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs for graft-versus-host disease.
    Kekre N; Antin JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):209-18. PubMed ID: 27007595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.
    Zhao Y; Shi J; Luo Y; Gao F; Tan Y; Lai X; Yu J; Wei G; Huang H
    Biol Blood Marrow Transplant; 2020 May; 26(5):e128-e133. PubMed ID: 31982545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
    Luu Tran H; Mahmoudjafari Z; Rockey M; Henry D; Grauer D; Aljitawi O; Abhyankar S; Ganguly S; Lin T; McGuirk J
    J Oncol Pharm Pract; 2016 Apr; 22(2):228-34. PubMed ID: 25471252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A Systematic Review.
    Ali AM; DiPersio JF; Schroeder MA
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1552-1564. PubMed ID: 27158050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease.
    Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Borjas-Almaguer OD; González-Llano O; Jaime-Pérez JC; Solano-Genesta M; Gómez-Guijosa M; Mancias-Guerra C; Tarin L; Gómez-Almaguer D
    Haematologica; 2012 May; 97(5):717-22. PubMed ID: 22133770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation.
    Iliopoulou BP; Hsu K; Pérez-Cruz M; Tang SW; Pang WW; Erkers T; Kambham N; Freeman GJ; Dekruyff RH; Meyer EH
    Blood Adv; 2019 Nov; 3(21):3419-3431. PubMed ID: 31714958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease.
    Danylesko I; Bukauskas A; Paulson M; Peceliunas V; Gedde-Dahl D Y T; Shimoni A; Shouval R; Griskevicius L; Floisand Y; Nagler A
    Bone Marrow Transplant; 2019 Jul; 54(7):987-993. PubMed ID: 30356163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.